Table 1 Baseline demographics and comorbid conditions in EVOLVE-1, EVOLVE-2 and REGAIN studies
Placebo (N = 1451) | GMB 120 mg (N = 705) | GMB 240 mg (N = 730) | |
|---|---|---|---|
Demographics | |||
Age, mean years, (SD) | 41.8 (11.6) | 40.8 (11.5) | 40.4 (11.9) |
Gender (female), n (%) | 1237 (85.3) | 599 (85.0) | 609 (83.4) |
Race, n (%) | |||
White | 1112 (76.6) | 545 (77.3) | a555 (76.1) |
Black or African American | 117 (8.1) | 53 (7.5) | a59 (8.1) |
Asian | 89 (6.1) | 48 (6.8) | a42 (5.8) |
American Indian or native Alaska | 24 (1.7) | 10 (1.4) | a16 (2.2) |
Native Hawaiian or other pacific islander | 2 (0.1) | 0 | a4 (0.6) |
Multiple | 107 (7.4) | 49 (7.0) | a53 (7.3) |
Region, n (%) | |||
North America | 977 (67.3) | 472 (67.0) | 496 (68.0) |
Europe | 262 (18.1) | 126 (17.9) | 131 (18.0) |
Other | 212 (14.6) | 107 (15.2) | 103 (14.1) |
Years since migraine diagnosis, mean (SD) | 21.1 (12.7) | 20.7 (12.5) | 19.6 (12.3) |
Comorbid conditions that occurred in > 10% of all participants, n (%) | |||
Seasonal allergy | 307 (21.2) | 158 (22.4) | 122 (16.7) |
Drug hypersensitivity | 247 (17.0) | 123 (17.5) | 128 (17.5) |
Insomnia | 165 (11.4) | 89 (12.6) | 78 (10.7) |
Anxiety | 166 (11.4) | 82 (11.6) | 81 (11.1) |
Depression | 181 (12.5) | 84 (11.9) | 79 (10.8) |
Back pain | 151 (10.4) | 62 (8.8) | 75 (10.3) |